Compare TRIB & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | BLRX |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 12.6M |
| IPO Year | 1996 | 2010 |
| Metric | TRIB | BLRX |
|---|---|---|
| Price | $0.77 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 152.0K | 9.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $2.30 |
| 52 Week High | $3.44 | $7.77 |
| Indicator | TRIB | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 41.70 |
| Support Level | $0.65 | $2.66 |
| Resistance Level | $0.79 | $3.11 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 84.28 | 23.92 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.